Literature DB >> 20609866

The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization.

Mauro Pagani1.   

Abstract

The number of drugs used for the treatment of different types of cancers is constantly increasing and actually exceeds 100 distinct chemical formulations. The use of most cytotoxic agents is associated with potential hypersensitivity reactions, and the constant increase of their administration has caused an increase in incidence of these adverse effects, thus becoming a relevant problem for clinicians. Hypersensitivity reactions are common with platinum compounds, L-asparaginase, taxanes, procarbazine, and epipodophyllotoxins, whereas they are unusual, but always possible, with the other chemotherapeutic drugs. Reactions associated with individual drugs are discussed in detail. The mechanism underlying these hypersensitivity reactions involves IgE-mediated hypersensitivity reactions, nonallergic hypersensitivity reactions, and a few pathogenetically unclear reactions. More studies are needed to better understand, diagnose, treat, and prevent these reactions. To achieve this goal, a multidisciplinary approach to treat patients with cancer who have potential allergies is needed. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609866     DOI: 10.1016/j.mcna.2010.03.002

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  10 in total

1.  Carboplatin-induced Kounis syndrome.

Authors:  Matteo Baroni; Sarah Todd; Francesco Pattarino; Flavio Doni
Journal:  J Cardiol Cases       Date:  2011-05-06

Review 2.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

3.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Authors:  J Boulanger; J N Boursiquot; G Cournoyer; J Lemieux; M S Masse; K Almanric; M P Guay
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

Review 4.  Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer.

Authors:  Antonio Ruggiero; Silvia Triarico; Giovanna Trombatore; Andrea Battista; Fabiola Dell'acqua; Carmelo Rizzari; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2013-06-14       Impact factor: 2.953

5.  Effectiveness of oxaliplatin desensitization protocols.

Authors:  Susana Cortijo-Cascajares; Inmaculada Nacle-López; Ignacio García-Escobar; María José Aguilella-Vizcaíno; Alberto Herreros-de-Tejada; Hernán Cortés-Funes Castro; Miguel-Ángel Calleja-Hernández
Journal:  Clin Transl Oncol       Date:  2012-07-25       Impact factor: 3.405

6.  Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.

Authors:  Kaori Kadoyama; Akiko Kuwahara; Motohiro Yamamori; J B Brown; Toshiyuki Sakaeda; Yasushi Okuno
Journal:  J Exp Clin Cancer Res       Date:  2011-10-05

Review 7.  Hypersensitivity to Carboplatin in Children with Malignancy.

Authors:  Antonio Ruggiero; Daniela Rizzo; Martina Catalano; Giorgio Attinà; Riccardo Riccardi
Journal:  Front Pharmacol       Date:  2017-04-12       Impact factor: 5.810

Review 8.  Omalizumab for successful chemotherapy desensitisation: What we know so far.

Authors:  Roxana Silvia Bumbacea; Selda Ali; Sabina Loredana Corcea; Luiza Spiru; Cornelia Nitipir; Victor Strambu; Dragos Bumbacea
Journal:  Clin Transl Allergy       Date:  2021-12-13       Impact factor: 5.871

9.  Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.

Authors:  Nóra Kutszegi; Ágnes F Semsei; András Gézsi; Judit C Sági; Viktória Nagy; Katalin Csordás; Zsuzsanna Jakab; Orsolya Lautner-Csorba; Krisztina Míta Gábor; Gábor T Kovács; Dániel J Erdélyi; Csaba Szalai
Journal:  PLoS One       Date:  2015-10-12       Impact factor: 3.240

10.  Inhibition of Angiogenesis by Treatment with Cold Atmospheric Plasma as a Promising Therapeutic Approach in Oncology.

Authors:  Lyubomir Haralambiev; Ole Neuffer; Andreas Nitsch; Nele C Kross; Sander Bekeschus; Peter Hinz; Alexander Mustea; Axel Ekkernkamp; Denis Gümbel; Matthias B Stope
Journal:  Int J Mol Sci       Date:  2020-09-26       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.